AmebaGone
Dr. Marcin Filutowicz, founded AmebaGone, Inc. in 2010 to commercialize a novel technology based upon the unique potential of free-living professional phagocytes (Dictyostelids or Dicty), found in soil and many other environments worldwide, to combat disease-causing microbes in affecting plants, water quality and human health.
Dr. Filutowicz and Katarzyna Borys from the Bacteriology Department of University of Wisconsin-Madison conceived the core technology. The inventors have assigned title for their work to AmebaGone and have executed a license to a collection of source material amassed by Dr. Kenneth Raper (also UW-Madison) with the Wisconsin Alumni Research Foundation (WARF). Filutowicz has developed biocontrol countermeasures to reduce infections caused by antibiotic-resistant bacteria since 1999. Dr. Filutowicz is a serial innovator, having co-founded ConjuGon Inc. in 2001 after inventing its technology. ConjuGon (now Atterx Biotherapeutics) is developing therapeutics to treat human bacterial infections. ConjuGon raised over $18M to advance its technology and is currently in Phase III clinical trials.
This person is not in any offices
AmebaGone
AmebaGone uses naturally occurring, soil-dwelling amoebae (Dictyostelids) as drugs and disinfectants in agriculture, medicine, and industry. The amoebae kill bacteria, antibiotic-resistant or not, by consuming them as their food source. Additionally, the amoebae can break down biofilms and consume the bacteria within. Biofilms pose significant problems for agriculture, medicine, and industry because conventional antimicrobials and disinfectants have little to no effect against them. AmebaGone, Inc. is developing proprietary technologies that use a novel biocontrol method to destroy persistent bacterial infections.